Limits...
Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.

Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Yamanaka H, Miyasaka N - Rheumatology (Oxford) (2014)

Bottom Line: Clinical, functional and structural outcomes were compared between those who continued and those who discontinued abatacept.Those attaining DAS28-CRP < 2.3 or < 2.7 without abatacept at the endpoint had significantly lower HAQ-DI score and/or CRP at enrolment.Non-serious adverse events occurred in three patients who continued or resumed abatacept.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Department of Rheumatology, Matsubara Mayflower Hospital, Kato, Department of Rheumatology, Taga General Hospital, Hitachi, Division of Rheumatology and Clinical Immunology, Department of Medicine, Sapporo City General Hospital, Sapporo, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Hospital, Kitakyushu, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo and Tokyo Medical and Dental University, Tokyo, Japan. tsutake@z5.keio.jp.

Show MeSH

Related in: MedlinePlus

Transition diagram of HAQ-DIDI: Disability Index.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4372674&req=5

keu338-F3: Transition diagram of HAQ-DIDI: Disability Index.

Mentions: In contrast to consistently low (<2.6) scores in the continuation group, the mean DAS28-ESR score in the discontinuation group increased slightly, from 2.4 at baseline to 2.7 at week 4, 3.1 at week 12, 3.3 at week 24, 3.5 at week 36 and 3.6 at week 52. According to the endpoint DAS28-ESR scores, 24.2% of the discontinuing vs 47.1% of the continuing patients were in remission, 30.3% vs 35.3% had LDA, 27.3% vs 17.6% had MDA and 18.2% vs 0% had HDA. The mean HAQ-DI scores for the two groups followed similar time courses and were 0.6 for both groups at week 52 (P = 0.920; Fig. 3).Fig. 3


Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.

Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Yamanaka H, Miyasaka N - Rheumatology (Oxford) (2014)

Transition diagram of HAQ-DIDI: Disability Index.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4372674&req=5

keu338-F3: Transition diagram of HAQ-DIDI: Disability Index.
Mentions: In contrast to consistently low (<2.6) scores in the continuation group, the mean DAS28-ESR score in the discontinuation group increased slightly, from 2.4 at baseline to 2.7 at week 4, 3.1 at week 12, 3.3 at week 24, 3.5 at week 36 and 3.6 at week 52. According to the endpoint DAS28-ESR scores, 24.2% of the discontinuing vs 47.1% of the continuing patients were in remission, 30.3% vs 35.3% had LDA, 27.3% vs 17.6% had MDA and 18.2% vs 0% had HDA. The mean HAQ-DI scores for the two groups followed similar time courses and were 0.6 for both groups at week 52 (P = 0.920; Fig. 3).Fig. 3

Bottom Line: Clinical, functional and structural outcomes were compared between those who continued and those who discontinued abatacept.Those attaining DAS28-CRP < 2.3 or < 2.7 without abatacept at the endpoint had significantly lower HAQ-DI score and/or CRP at enrolment.Non-serious adverse events occurred in three patients who continued or resumed abatacept.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Department of Rheumatology, Matsubara Mayflower Hospital, Kato, Department of Rheumatology, Taga General Hospital, Hitachi, Division of Rheumatology and Clinical Immunology, Department of Medicine, Sapporo City General Hospital, Sapporo, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Hospital, Kitakyushu, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo and Tokyo Medical and Dental University, Tokyo, Japan. tsutake@z5.keio.jp.

Show MeSH
Related in: MedlinePlus